{"id":54523,"date":"2023-03-06T15:07:44","date_gmt":"2023-03-06T14:07:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/"},"modified":"2023-03-06T15:07:44","modified_gmt":"2023-03-06T14:07:44","slug":"university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/","title":{"rendered":"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers"},"content":{"rendered":"
\n

BOSTON & LAUSANNE, Switzerland–(BUSINESS WIRE)–SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS\u2019 platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM\u2122 platform to gain deeper insights into hematologic malignancies.\n<\/p>\n

<\/a><\/p>\n

\nAs the only health sciences university in the state of Arkansas and the state\u2019s largest public employer, UAMS is a cornerstone of medical research and treatment for the state. SOPHiA DDM\u2122 is a cloud-based platform that uses Artificial Intelligence with patented technologies and methods to synthesize next generation sequencing (NGS) data. Such synthesis is key to identifying characterizations of disease-causing mutations.\n<\/p>\n

\n\u201cOur mission at SOPHiA GENETICS is to democratize data-driven medicine, making it more accessible to all,\u201d said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS. \u201cThe adoption of SOPHiA DDM\u2122 for UAMS \u2013 Arkansas\u2019 only health sciences university \u2013 will benefit the entire state and larger medical community by providing the institution with more comprehensive insights from their data.\u201d\n<\/p>\n

\nHematologic malignancies such as leukemia, lymphoma, or plasma cell myeloma can move fast. Clinical researchers need to be able to move quickly as well. Having the ability to synthesize NGS data in-house builds local expertise and allows for faster data turnaround, a benefit to both clinical researchers and patients.\n<\/p>\n

\nHematological tumors represent the fourth most frequent cancer type in the developed world.1<\/sup> The SOPHiA DDM\u2122 for Blood Cancers solution is designed to accelerate and streamline the analyses of blood cancers and positively impact disease management.\n<\/p>\n

\n\u201cWe\u2019re excited to bring this technology to the state of Arkansas,\u201d said Philippe Menu, Chief Medical Officer, SOPHiA GENETICS. \u201cOne person in the U.S. is diagnosed with leukemia, lymphoma, or myeloma roughly every three minutes2<\/sup>. The SOPHiA DDM\u2122 for Blood Cancers solution will put increased data at the fingertips of clinical researchers.\u201d\n<\/p>\n

\nFor more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM<\/a>, or connect on Twitter<\/a>, LinkedIn<\/a>, <\/b>Facebook<\/a>, and Instagram<\/a>.\n<\/p>\n

\nAbout SOPHiA GENETICS<\/b>\n<\/p>\n

\nSOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM\u2122 Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM\u2122 Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM<\/a>, or connect on Twitter<\/a>, LinkedIn<\/a>, <\/b>Facebook<\/a>, and Instagram<\/a>. Where others see data, we see answers.<\/b>\n<\/p>\n

\nSOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com<\/a> to obtain the appropriate product information for your country of residence.<\/i>\n<\/p>\n

\nSOPHiA GENETICS Forward-Looking Statements:<\/i><\/b>\n<\/p>\n

\nThis press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management\u2019s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.<\/i>\n<\/p>\n

\nAbout UAMS<\/b>\n<\/p>\n

\nUAMS is the state’s only health sciences university, with colleges of Medicine, Nursing, Pharmacy, Health Professions and Public Health; a graduate school; a hospital; a main campus in Little Rock; a Northwest Arkansas regional campus in Fayetteville; a statewide network of regional campuses; and seven institutes: the Winthrop P. Rockefeller Cancer Institute, Jackson T. Stephens Spine & Neurosciences Institute, Harvey & Bernice Jones Eye Institute, Psychiatric Research Institute, Donald W. Reynolds Institute on Aging, Translational Research Institute and Institute for Digital Health & Innovation. UAMS includes UAMS Health, a statewide health system that encompasses all of UAMS’ clinical enterprise. UAMS is the only adult Level 1 trauma center in the state. UAMS has 3,240 students, 913 medical residents and fellows, and five dental residents. It is the state’s largest public employer with more than 11,000 employees, including 1,200 physicians who provide care to patients at UAMS, its regional campuses, Arkansas Children’s, the VA Medical Center and Baptist Health. Visit www.uams.edu<\/a> or uamshealth.com<\/a>. Find us on Facebook<\/a>, Twitter<\/a>, YouTube<\/a> or Instagram<\/a>.\n<\/p>\n

\n1<\/sup> https:\/\/gco.iarc.fr\/today\/fact-sheets-cancers<\/a> accessed on May 19th, 2021.\n<\/p>\n

\n2<\/sup> https:\/\/www.lls.org\/facts-and-statistics\/facts-and-statistics-overview#:~:text=Approximately%20every%209%20minutes%2C%20someone,than%20six%20people%20every%20hour<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:
\n
<\/b>Nick Puleo
\n
npuleo@comsint.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON & LAUSANNE, Switzerland–(BUSINESS WIRE)–SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS\u2019 platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM\u2122 platform to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54523","6":"format-standard","7":"category-industry"},"yoast_head":"\nUniversity of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON & LAUSANNE, Switzerland–(BUSINESS WIRE)–SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS\u2019 platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM\u2122 platform to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-06T14:07:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230306005157\/en\/1681846\/21\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers\",\"datePublished\":\"2023-03-06T14:07:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/\"},\"wordCount\":945,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005157\\\/en\\\/1681846\\\/21\\\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/\",\"name\":\"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005157\\\/en\\\/1681846\\\/21\\\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg\",\"datePublished\":\"2023-03-06T14:07:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005157\\\/en\\\/1681846\\\/21\\\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005157\\\/en\\\/1681846\\\/21\\\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/","og_locale":"en_US","og_type":"article","og_title":"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers - Pharma Trend","og_description":"BOSTON & LAUSANNE, Switzerland–(BUSINESS WIRE)–SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS\u2019 platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM\u2122 platform to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-06T14:07:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230306005157\/en\/1681846\/21\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers","datePublished":"2023-03-06T14:07:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/"},"wordCount":945,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230306005157\/en\/1681846\/21\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/","url":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/","name":"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230306005157\/en\/1681846\/21\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg","datePublished":"2023-03-06T14:07:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230306005157\/en\/1681846\/21\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230306005157\/en\/1681846\/21\/SOPHiA_GENETICS_Stacked_RGB_%285%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/university-of-arkansas-for-medical-sciences-will-use-sophia-genetics-to-advance-clinical-research-for-blood-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54523"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54523\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}